Search
Search
Journalism from the heart of crises
  1. Home
  2. Africa

Generic ARV gets tentative approval from FDA

    JOHANNESBURG
    Indian pharmaceutical company Ranbaxy has received 'tentative approval' from the US Food and Drug Administration (FDA) for its generic version of an antiretroviral (ARV) drug. Lamivudine (3TC) is the first ARV from an Indian manufacturer to be approved by the US drug regulator for purchase by the President's Emergency Plan for AIDS Relief (PEPFAR), the KaiserNetwork news service reported. This means that the medication is considered equivalent to the patented product and can be used in the $15 billion PEPFAR programme, which directs money to 12 African nations and the Caribbean. The FDA has expedited its review procedure for ARVs to allow the US government to purchase cheaper versions of the life-prolonging medication.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Get the day’s top headlines in your inbox every morning

    Starting at just $5 a month, you can become a member of The New Humanitarian and receive our premium newsletter, DAWNS Digest.

    DAWNS Digest has been the trusted essential morning read for global aid and foreign policy professionals for more than 10 years.

    Government, media, global governance organisations, NGOs, academics, and more subscribe to DAWNS to receive the day’s top global headlines of news and analysis in their inboxes every weekday morning.

    It’s the perfect way to start your day.

    Become a member of The New Humanitarian today and you’ll automatically be subscribed to DAWNS Digest – free of charge.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join